BNP Paribas Asset Management’s Theravance Biopharma TBPH Stock Holding History

BNP Paribas Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.4K	Buy	+1,136	New	+$20.1K	﹤0.01%	2064
2018 Q3	–	Sell	-238,015	Closed	-$5.4M	–	949
2018 Q2	$5.4M	Buy	238,015 +15,032	+7%	+$357K	0.05%	463
2018 Q1	$5.41M	Buy	222,983 +46,791	+27%	+$1.29M	0.05%	466
2017 Q4	$4.91M	Buy	176,192 +1,368	+0.8%	+$40.5K	0.04%	491
2017 Q3	$5.99M	Buy	174,824 +12,069	+7%	+$395K	0.05%	449
2017 Q2	$6.48M	Buy	+162,755	New	+$6.26M	0.06%	437

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BNP Paribas Asset Management's TBPH Position: Q1 2026 in Review

BNP Paribas Asset Management opened a new position in Theravance Biopharma (TBPH) in Q1 2026: 1,136 shares worth $18.4K. The stake represents ﹤0.01% of the portfolio and ranks #2064 among its holdings. This is a return to the name: BNP Paribas Asset Management previously reported a position in TBPH as recently as Q2 2018.

BNP Paribas Asset Management first reported a position in TBPH in Q2 2017 and has held it in 6 quarters since. The position peaked at $6.48M in Q2 2017. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

BNP Paribas Asset Management held 1,136 shares of Theravance Biopharma worth $18.4K as of Q1 2026.
Theravance Biopharma was a new BNP Paribas Asset Management position in Q1 2026.
Theravance Biopharma made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #2064 holding.
BNP Paribas Asset Management first reported a position in Theravance Biopharma in Q2 2017 and has held it in 6 quarters since.
BNP Paribas Asset Management's Theravance Biopharma position peaked at $6.48M in Q2 2017.
173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.